RxDoctor Payments Data

Scott Lucchese, MD

Neurology · Little Rock, ARNPI 1699877712

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (39.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 74.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $651 and has fallen 98.2% since, to $12 in 2022. That places this record below the midpoint for neurology clinicians in AR, where the typical reported total is $1,072.

$826in general payments, 2019–2025

Across 18 payments — averaging $45.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$618
  • EMD Serono, Inc.$78
  • Novartis$52
  • E.r. Squibb & Sons, L.L.C.$30
  • Sunovion Pharmaceuticals Inc.$24
  • Catalyst Pharmaceuticals, Inc.$12
  • plus $12 from 1 others

What the payments were for

  • Speaking & faculty fees$30036%
  • Food & beverage$20224%
  • Education$32439%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$826 in reported general payments places this provider in the 45th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$51,134
Medicare patients
154
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant88$112,631
QuliptaAtogepant91$103,645
Aimovig AutoinjectorErenumab-Aooe54$41,546
Nurtec OdtRimegepant Sulfate23$40,583
Emgality PenGalcanezumab-Gnlm53$39,309
Celecoxib104$7,939
Butorphanol Tartrate81$5,368
Acetazolamide56$3,957
Lisdexamfetamine Dimesylate11$2,630
Nortriptyline Hcl172$1,882
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine79$1,816
Baclofen73$1,378
Ondansetron OdtOndansetron50$1,252
Potassium Citrate ErPotassium Citrate31$1,215
Fludrocortisone Acetate73$1,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$618$216,277179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 93 neurology providers in Arkansas.

Other neurology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →